Table 3 Clinical outcomes of CRC patients with MTB or MK infection
Patient | Diagnosis method for MTB or MK infection | Treatment of MTB or MK | Time from the beginning of MTB or MK therapy until the start of first-line chemotherapy (days) | MTB or MK treatment success |
|---|---|---|---|---|
A | CT imaging | 6HRE/6HR | 16 | Completion |
B | Sputum TB-PCR (+), MTB culture (+) | 2HREZ/7HR | 104 | Cure |
C | Sputum smear (+), MTB culture (+) | 24HE | 408 | Cure |
D | Sputum smear (+), MK culture (+) | 18HRE | 56 | Cure |
E | Sputum smear (-), MTB culture (+) | 9HRE | 25 | Cure |
F | Sputum smear (-), Sputum TB-PCR (+), MTB culture (+) | 6HRE/6HR | 19 | Cure |
G | Sputum smear (+), MTB culture (+) | 12RE | 53 | Cure |
Patient | First-line chemotherapy Regimen | Best response | Side effects (grade ≥ 3) due to cancer chemotherapy or MTB or MK treatment | |
A | UFT/LV | SD | - | |
B | FOLFOX6 + Cmab | CR | - | |
C | FOLFOX6 | PD | Liver dysfunction due to MTB treatment | |
D | FOLFOX6 + Pmab | PD | - | |
E | FOLFOX6 + Bmab | SD | Hemoptysis due to Bmab | |
F | FOLFOX6 | PR | - | |
G | FOLFIRI | PD | - | |